ArticleBiomarker insights2006
Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer.
Article in Biomarker insights, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Characterization of pritumumab in murine models and primate safety study.Scientific reports · 2025Article
- Chito-oligosaccharide impairs the proliferation, invasion and migration of pancreatic cancer cells.Discover oncology · 2025Article
- Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens.JCI insight · 2023Article
- Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications.Biomedicines · 2023Article
- Vimentin immunoexpression and its prognostic activity in colon cancer among Caucasian patients.Przeglad gastroenterologiczny · 2022Article
- Protein citrullination as a source of cancer neoantigens.Journal for immunotherapy of cancer · 2021Article
- Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.OncoTargets and therapy · 2021Review
- Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.American journal of cancer research · 2018Review
- Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis.Molecular cancer research : MCR · 2017Article
- Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Association of Cytokeratin and Vimentin Protein in the Genesis of Transitional Cell Carcinoma of Urinary Bladder Patients.Disease markers · 2015Article
- The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract.Przeglad gastroenterologiczny · 2015Review
- Early diagnosis of pancreatic cancer: challenges and new developments.Biomarkers in medicine · 2012Review
- Vimentin in cancer and its potential as a molecular target for cancer therapy.Cellular and molecular life sciences : CMLS · 2011Review
- Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.British journal of cancer · 2011Article
- Prevention of Soil-transmitted Helminth Infection.Journal of global infectious diseases · 2011Article
- Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2010Article
- Article
- Improving seroreactivity-based detection of glioma.Neoplasia (New York, N.Y.) · 2009Article
- The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray.Electrophoresis · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Pancreatic cancer has a poor prognosis, in part due to lack of early detection. The identification of circulating tumor antigens or their related autoantibodies provides a means for early cancer diagnosis. We have used a proteomic approach to identify proteins that commonly induce a humoral response in pancreatic cancer. Proteins from a pancreatic adenocarcinoma cell line (Panc-1) were subjected to two-dimensional PAGE, followed by Western blot analysis in which individual sera were tested for autoantibodies. Sera from 36 newly diagnosed patients with pancreatic cancer, 18 patients with chronic pancreatitis and 15 healthy subjects were analyzed. Autoantibodies were detected against a protein identified by mass spectrometry as vimentin, in sera from 16/36 patients with pancreatic cancer (44.4%). Only one of 18 chronic pancreatitis patients and none of the healthy controls exhibited reactivity against this vimentin isoform. Interestingly, none of several other isoforms of vimentin detectable in 2-D gels exhibited reactivity with patient sera. Vimentin protein expression levels were investigated by comparing the integrated intensity of spots visualized in 2-D PAGE gels of various cancers. Pancreatic tumor tissues showed greater than a 3-fold higher expression of total vimentin protein than did the lung, colon, and ovarian tumors that were analyzed. The specific antigenic isoform was found at 5-10 fold higher levels. The detection of autoantibodies to this specific isoform of vimentin may have utility for the early diagnosis of pancreatic cancer.
Identifiers
18769604PMC2528299W2101200822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.